CDKN1B and ovarian carcinoma: It targets CDKN1B (cyclin-dependent kinase inhibitor 1B) and ING5 (inhibitor of growth family member 5), and cancer-associated adipocytes, leading to paclitaxel resistance in ovarian cancer cells due to the transfer of miR-21, which binds to the APAF1 (apoptotic protease activating factor 1) coding sequence and suppresses APAF1 expression [196,197].